It was approved for use in the treatment of seizures associated with SCN1A Dravet syndrome (and subsequently for Lennox-Gastaut Syndrome) in patients 2 years of age and older with a warning of valvular heart disease and pulmonary hypertension. This evidence concerns the gene SCN1A and heart valve disorder.